Early Phase 1 Parkinson's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are already enrolled in the PPMI Clinical protocol as either a prodromal Parkinson's disease participant or a healthy participant
- People with Parkinson's disease who are already enrolled in the PPMI Clinical protocol and have not yet started medication to treat their symptoms at the time of joining, or within the first 2 years of taking part
- People who are able to give their informed consent to participate
- People whose genetic screening results show they are a "high binder" at a specific gene variant known as TSPO rs6971
- Men, or women who meet additional criteria around pregnancy and contraception (see below)
- Women who are not able to become pregnant — meaning they have had no periods for at least 12 months before the scan, or have had a surgical procedure such as tubal ligation, removal of both ovaries, or a hysterectomy
- Women who are able to become pregnant and are using a highly effective form of birth control for at least 14 days before and 24 hours after the scan — for example, oral contraceptives used for at least 3 months, an IUD in place for at least 2 months, or barrier methods such as a diaphragm or condom combined with spermicide (note: periodic abstinence methods are not considered acceptable under the trial criteria)
- Women who are able to become pregnant must not be pregnant, breastfeeding, or lactating, and must have a negative pregnancy test on the day of the scan before the injection
Who may not be able to join:
- People who have received a total radiation exposure of 50 millisieverts (mSv) or more to the whole body in the past year (this is the annual limit set by US federal regulations)
- People who have another medical or psychiatric condition, or abnormal lab results, that the trial site investigator believes would make participation unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jonathan McConathy, MD, PhD, University of Alabama at Birmingham
Phone: 205-934-6499
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Measure baseline and follow up regional brain TSPO levels using [18F]DPA-714-PET in prodromal PD.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.